These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 18977120)

  • 1. No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy.
    Lynch JM; Tate SK; Kinirons P; Weale ME; Cavalleri GL; Depondt C; Murphy K; O'Rourke D; Doherty CP; Shianna KV; Wood NW; Sander JW; Delanty N; Goldstein DB; Sisodiya SM
    Epilepsy Res; 2009 Jan; 83(1):44-51. PubMed ID: 18977120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
    Lynch BA; Lambeng N; Nocka K; Kensel-Hammes P; Bajjalieh SM; Matagne A; Fuks B
    Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9861-6. PubMed ID: 15210974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rare protein sequence variation in SV2A gene does not affect response to levetiracetam.
    Dibbens LM; Hodgson BL; Helbig KL; Oliver KL; Mulley JC; Berkovic SF; Scheffer IE
    Epilepsy Res; 2012 Sep; 101(3):277-9. PubMed ID: 22551666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levetiracetam-induced a new seizure type in a girl with a novel SV2A gene mutation.
    Wang D; Zhou Q; Ren L; Lin Y; Gao L; Du J; Wang Y
    Clin Neurol Neurosurg; 2019 Jun; 181():64-66. PubMed ID: 31005049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synaptic vesicle protein 2A tumoral expression predicts levetiracetam adverse events.
    Romoli M; Mandarano M; Romozzi M; Eusebi P; Bedetti C; Nardi Cesarini E; Verzina A; Calvello C; Loreti E; Sidoni A; Giovenali P; Calabresi P; Costa C
    J Neurol; 2019 Sep; 266(9):2273-2276. PubMed ID: 31168673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homozygous Mutation in Synaptic Vesicle Glycoprotein 2A Gene Results in Intractable Epilepsy, Involuntary Movements, Microcephaly, and Developmental and Growth Retardation.
    Serajee FJ; Huq AM
    Pediatr Neurol; 2015 Jun; 52(6):642-6.e1. PubMed ID: 26002053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy.
    van Vliet EA; Aronica E; Redeker S; Boer K; Gorter JA
    Epilepsia; 2009 Mar; 50(3):422-33. PubMed ID: 18717715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levetiracetam resistance: Synaptic signatures & corresponding promoter SNPs in epileptic hippocampi.
    Grimminger T; Pernhorst K; Surges R; Niehusmann P; Priebe L; von Lehe M; Hoffmann P; Cichon S; Schoch S; Becker AJ
    Neurobiol Dis; 2013 Dec; 60():115-25. PubMed ID: 24018139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression profile of synaptic vesicle glycoprotein 2A, B, and C paralogues in temporal neocortex tissue from patients with temporal lobe epilepsy (TLE).
    Pazarlar BA; Aripaka SS; Petukhov V; Pinborg L; Khodosevich K; Mikkelsen JD
    Mol Brain; 2022 May; 15(1):45. PubMed ID: 35578248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD; Gillard M
    Epilepsia; 2017 Feb; 58(2):255-262. PubMed ID: 28012162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levetiracetam.
    Krishna K; Raut AL; Gohel KH; Dave P
    J Assoc Physicians India; 2011 Oct; 59():656-8. PubMed ID: 22479748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cortico-hippocampal hyperexcitability in synapsin I/II/III knockout mice: age-dependency and response to the antiepileptic drug levetiracetam.
    Boido D; Farisello P; Cesca F; Ferrea E; Valtorta F; Benfenati F; Baldelli P
    Neuroscience; 2010 Nov; 171(1):268-83. PubMed ID: 20804820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam.
    Kaminski RM; Gillard M; Leclercq K; Hanon E; Lorent G; Dassesse D; Matagne A; Klitgaard H
    Epilepsia; 2009 Jul; 50(7):1729-40. PubMed ID: 19486357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining modelling and mutagenesis studies of synaptic vesicle protein 2A to identify a series of residues involved in racetam binding.
    Shi J; Anderson D; Lynch BA; Castaigne JG; Foerch P; Lebon F
    Biochem Soc Trans; 2011 Oct; 39(5):1341-7. PubMed ID: 21936812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiepileptic effects of levetiracetam in a rodent neonatal seizure model.
    Talos DM; Chang M; Kosaras B; Fitzgerald E; Murphy A; Folkerth RD; Jensen FE
    Pediatr Res; 2013 Jan; 73(1):24-30. PubMed ID: 23138400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of SV2 isoforms during rodent brain development.
    Crèvecœur J; Foerch P; Doupagne M; Thielen C; Vandenplas C; Moonen G; Deprez M; Rogister B
    BMC Neurosci; 2013 Aug; 14():87. PubMed ID: 23937191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
    Klitgaard H; Matagne A; Nicolas JM; Gillard M; Lamberty Y; De Ryck M; Kaminski RM; Leclercq K; Niespodziany I; Wolff C; Wood M; Hannestad J; Kervyn S; Kenda B
    Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein.
    Gillard M; Chatelain P; Fuks B
    Eur J Pharmacol; 2006 Apr; 536(1-2):102-8. PubMed ID: 16556440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond.
    Löscher W; Gillard M; Sands ZA; Kaminski RM; Klitgaard H
    CNS Drugs; 2016 Nov; 30(11):1055-1077. PubMed ID: 27752944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the In Vivo Specificity of [
    Serrano ME; Becker G; Bahri MA; Seret A; Mestdagh N; Mercier J; Mievis F; Giacomelli F; Lemaire C; Salmon E; Luxen A; Plenevaux A
    Molecules; 2019 May; 24(9):. PubMed ID: 31052478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.